The Deadly Cough Syrup Crisis: Child Deaths in Chhindwara and Rajasthan

 

The Deadly Cough Syrup Crisis: Child Deaths in Chhindwara and Rajasthan

In the quiet districts of Madhya Pradesh and Rajasthan, a heartbreaking health crisis has unfolded, claiming the lives of at least 11 young children in just two weeks—nine in Madhya Pradesh's Chhindwara district and two in Rajasthan. What began as routine seasonal illnesses—colds, fevers, and coughs—spiraled into a nightmare of kidney failure and sudden deaths. Investigations point to contaminated cough syrups as the prime suspect.

As of October 3, 2025, inquiries are ongoing, but the tragedy is a stark reminder of the vulnerabilities in India’s pharmaceutical supply chain—and the recurring pattern where government action comes only after fatalities occur.

1. The Tragedy Unfolds

The crisis first emerged in Chhindwara, where six children under five died of acute kidney failure between mid-September and early October. By October 1, the toll had risen to nine. Similar cases surfaced in neighboring Rajasthan, including two more child deaths linked to suspected cough syrup use.

Victims had consumed syrups such as:

• Coldrif/Coldfref (Sresan Pharmaceuticals, Tamil Nadu)
• Nextro (manufacturer unspecified)
• Dextromethorphan hydrobromide syrup (Kaysons Pharma, Jaipur – batches KL-25/147, KL-25/148)

Symptoms started as viral-like infections but progressed rapidly to reduced urine output, swelling, and kidney failure. Parents described how their children initially improved, only to deteriorate fatally within days.

The echoes of past global scandals are chilling—such as the 2022 Gambia case, where Indian-made syrups containing diethylene glycol (DEG) killed over 60 children.

Currently, over 1,400 children in affected areas are under monitoring, with ASHA workers conducting door-to-door health checks. No infectious outbreak has been confirmed; suspicion remains firmly on chemical contamination.

2. Suspected Culprit: DEG-Contaminated Syrups

Investigators believe the syrups may have been adulterated with diethylene glycol (DEG), a toxic industrial solvent sometimes substituted for safe pharmaceutical excipients to cut costs.

• Toxic pathway: DEG poisoning causes gastrointestinal distress, acute kidney injury, and neurological damage. Children are especially vulnerable, often requiring urgent dialysis to survive.
• State bans: Madhya Pradesh has banned dextromethorphan syrups statewide, while Rajasthan halted 19 suspect batches. Tamil Nadu froze stocks at Sresan Pharmaceuticals’ plant.
• Testing underway: The National Centre for Disease Control (NCDC) and CSIR labs are analyzing samples; results are awaited.

India has faced similar tragedies before (2023, 2022, earlier decades). A clear pattern of lax quality control and weak enforcement emerges.

3. Government Response: Quick but Reactive

Authorities have scrambled to contain the fallout:

• Children with symptoms lasting over two days must now be observed at civil hospitals.
• Private doctors are barred from independently treating suspected viral cases.
• Statewide bans imposed on suspect syrups in MP and Rajasthan.
• Stocks frozen at Sresan Pharma in Tamil Nadu.

Yet critics argue the response is reactive. India’s regulator, the Central Drugs Standard Control Organisation (CDSCO), suffers from understaffing and weak post-marketing surveillance. Historically, bans follow deaths rather than proactive inspections.

4. Accountability: Who Is Responsible?

Actor	Role	Failures	Action Taken (Past & Present)
Manufacturers (Sresan Pharma, Kaysons Pharma)	Produce/test syrups	Skipping DEG testing; false certificates	Stock freezes, temporary suspensions, probes
Suppliers	Provide excipients	Supplying industrial-grade materials	Rarely prosecuted; weak traceability
Regulators (CDSCO/States)	Approve, inspect, recall	Weak inspections; delayed recalls	Investigations, but rarely arrests
Health Depts.	Distribute via schemes	No independent testing	Monitoring protocols introduced
Distributors/Pharmacies	Sell to consumers	Ignoring recalls	Minimal accountability so far

 

5. Precautions for Parents

• Avoid self-medication for children with OTC syrups.
• Check batch numbers before purchase.
• Buy only from licensed pharmacies.
• If poisoning suspected, rush to hospital immediately for supportive care (fluids, dialysis).
• Report suspect medicines to drug controllers and health authorities.

6. Legal Options for Parents

Families seeking justice have multiple legal remedies:

(a) Criminal Action

• Bharatiya Nyaya Sanhita (BNS), 2023
• Sec. 106 – Causing death by negligence.
• Sec. 276 & 277 – Adulteration and sale of adulterated drugs.
• Drugs & Cosmetics Act, 1940
• Sec. 27 – Life imprisonment for spurious/adulterated drugs.

👉 Parents can file FIRs and complaints with drug inspectors.

(b) Consumer Protection

• Compensation claims under the Consumer Protection Act, 2019 for defective products.
• Commissions at district, state, or national level depending on claim amount.
• Option for class action complaints.

(c) Medical Negligence

• Hospitals/pharmacies may be liable if they dispensed suspect syrups without diligence.
• Remedies via consumer courts or civil suits.

(d) Writs & PILs

• High Courts (Art. 226) or Supreme Court (Art. 32) for:
• Court-monitored probes (CBI/SIT).
• Interim compensation.
• Reforms in regulatory monitoring.

(e) Government Liability

If distributed under govt schemes, the state may be vicariously liable, as courts have held in vaccine/sterilization mishap cases.

7. Towards Systemic Reform

This tragedy highlights systemic issues:

• Weak enforcement of Good Manufacturing Practices (GMPs).
• Lack of routine raw material testing.
• Event-driven regulation instead of preventive inspections.
• Absence of fast-track compensation frameworks for victims.

International collaboration with WHO and stricter CDSCO-led oversight are urgently needed to prevent repeat disasters.

8. Demands from the Government

To ensure such tragedies are not repeated, urgent systemic reforms are needed. Families, activists, and public health experts demand that the Union and State Governments:

1. Mandatory DEG and PEG Testing

   • Require batch-wise testing of all syrups for toxic solvents like diethylene glycol (DEG) and ethylene glycol (EG) before market release.

2. Strengthen CDSCO and State Drug Regulators

   • Increase staffing, training, and funding for the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers.

   • Conduct risk-based inspections of pharma plants, not just paper audits.

3. Transparent Drug Recalls

   • Establish a public online database of banned/withdrawn batches accessible to parents, doctors, and pharmacists in real time.

4. Fast-Track Compensation Mechanism

   • Create a no-fault compensation fund for victims of contaminated drugs, ensuring families don’t spend years in courts.

5. Accountability for Manufacturers

   • Strictly enforce BNS 2023 and Drugs & Cosmetics Act provisions against negligent manufacturers, including criminal prosecutions and permanent license cancellations.

6. Independent Forensic Testing Labs

   • Expand government-run and NABL-accredited labs to ensure unbiased, rapid testing of drugs across all states.

7. Public Awareness Campaigns

   • Launch nationwide campaigns urging parents to avoid self-medicating children, verify medicines, and report adverse reactions.

8. Whistleblower Protection

   • Introduce legal protections for insiders in pharma companies who expose unsafe practices.

9. Conclusion

The Chhindwara cough syrup crisis is not just a local tragedy but a national alarm bell. Parents mourning their children must navigate complex legal paths for justice—from criminal prosecutions under the BNS to consumer claims, negligence suits, and constitutional remedies.

But beyond courtroom battles, the real solution lies in systemic reform—ensuring that profit never trumps child safety. Until then, each tragedy will only add to India’s grim list of preventable deaths. Children’s lives are too precious to be the price of regulatory failure.

#CoughSyrupCrisis #DrugSafety #PublicHealthCrisis #JusticeForChildren #PharmaAccountability